The Experts below are selected from a list of 288 Experts worldwide ranked by ideXlab platform
Saul Silverstein - One of the best experts on this subject based on the ideXlab platform.
-
restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild type varicella zoster virus isolates
Journal of Virology, 1992Co-Authors: Phillip Larussa, Sharon Steinberg, Anne A. Gershon, Octavian Lungu, Iain Hardy, Saul SilversteinAbstract:Abstract The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine Strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to Strain Identification of VZV in vesicular lesions.
Anne A. Gershon - One of the best experts on this subject based on the ideXlab platform.
-
Viral Strain Identification in varicella vaccinees with disseminated rashes.
Pediatric Infectious Disease Journal, 2000Co-Authors: Philip Larussa, Sharon Steinberg, Eugene D. Shapiro, Marietta Vázquez, Anne A. GershonAbstract:BACKGROUND: Approximately 15% of recipients of live attenuated varicella vaccine may develop mild breakthrough varicella months to years after immunization. Although some vaccinees will develop zoster, it is less common in recipients of vaccine than in those who have had natural varicella. OBJECTIVE: To determine the varicella-zoster virus (VZV) Strain responsible for breakthrough varicella and zoster in recipients of varicella vaccine. METHODS: A PCR assay capable of distinguishing wild-type from vaccine Strain VZV was performed on samples from skin lesions from vaccinees with breakthrough varicella and zoster. RESULTS: All of 57 vaccinees with breakthrough varicella, clinically diagnosed on the basis of a generalized maculopapular or vesicular rash, in which there was amplifiable DNA [corrected], had wild-type VZV infection based on analysis of viral DNA. The Oka vaccine Strain of VZV was not identified in any of these cases. In contrast, in 32 patients with zosteriform rashes, the vaccine Strain was identified in 22 samples, and the wild-type Strain was identified in 10 samples. CONCLUSIONS: Wild-type virus was identified in all generalized rashes occurring after the immediate 6-week postvaccination period. When reactivation of vaccine Strain occurred, it presented as typical zoster. We find no evidence that reactivation of vaccine virus occurs with the clinical picture of generalized rash.
-
restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild type varicella zoster virus isolates
Journal of Virology, 1992Co-Authors: Phillip Larussa, Sharon Steinberg, Anne A. Gershon, Octavian Lungu, Iain Hardy, Saul SilversteinAbstract:Abstract The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine Strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to Strain Identification of VZV in vesicular lesions.
Amy L Greer - One of the best experts on this subject based on the ideXlab platform.
-
early vaccine availability represents an important public health advance for the control of pandemic influenza
BMC Research Notes, 2015Co-Authors: Amy L GreerAbstract:Background Traditional processes for the production of pandemic influenza vaccines are not capable of producing a vaccine that could be deployed sooner than 5–6 months after Strain Identification. Plant-based vaccine technologies are of public health interest because they represent an opportunity to begin vaccinating earlier.
Sharon Steinberg - One of the best experts on this subject based on the ideXlab platform.
-
Viral Strain Identification in varicella vaccinees with disseminated rashes.
Pediatric Infectious Disease Journal, 2000Co-Authors: Philip Larussa, Sharon Steinberg, Eugene D. Shapiro, Marietta Vázquez, Anne A. GershonAbstract:BACKGROUND: Approximately 15% of recipients of live attenuated varicella vaccine may develop mild breakthrough varicella months to years after immunization. Although some vaccinees will develop zoster, it is less common in recipients of vaccine than in those who have had natural varicella. OBJECTIVE: To determine the varicella-zoster virus (VZV) Strain responsible for breakthrough varicella and zoster in recipients of varicella vaccine. METHODS: A PCR assay capable of distinguishing wild-type from vaccine Strain VZV was performed on samples from skin lesions from vaccinees with breakthrough varicella and zoster. RESULTS: All of 57 vaccinees with breakthrough varicella, clinically diagnosed on the basis of a generalized maculopapular or vesicular rash, in which there was amplifiable DNA [corrected], had wild-type VZV infection based on analysis of viral DNA. The Oka vaccine Strain of VZV was not identified in any of these cases. In contrast, in 32 patients with zosteriform rashes, the vaccine Strain was identified in 22 samples, and the wild-type Strain was identified in 10 samples. CONCLUSIONS: Wild-type virus was identified in all generalized rashes occurring after the immediate 6-week postvaccination period. When reactivation of vaccine Strain occurred, it presented as typical zoster. We find no evidence that reactivation of vaccine virus occurs with the clinical picture of generalized rash.
-
restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild type varicella zoster virus isolates
Journal of Virology, 1992Co-Authors: Phillip Larussa, Sharon Steinberg, Anne A. Gershon, Octavian Lungu, Iain Hardy, Saul SilversteinAbstract:Abstract The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine Strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to Strain Identification of VZV in vesicular lesions.
Phillip Larussa - One of the best experts on this subject based on the ideXlab platform.
-
restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild type varicella zoster virus isolates
Journal of Virology, 1992Co-Authors: Phillip Larussa, Sharon Steinberg, Anne A. Gershon, Octavian Lungu, Iain Hardy, Saul SilversteinAbstract:Abstract The nucleotide changes that result in two restriction endonuclease polymorphisms that differentiate wild-type varicella-zoster virus (VZV) from the vaccine Strain were determined. Oligonucleotide primers that flank these sites were used to amplify the intervening sequences with the polymerase chain reaction to identify VZV DNA in clinical isolates. Restriction enzyme digestion of the amplification products distinguished vaccine and wild-type genomes from one another. This study confirms the feasibility of amplifying VZV sequences so that they may be detected in clinical specimens and provides a molecular epidemiological approach to Strain Identification of VZV in vesicular lesions.
